To date, five ALK inhibitors have received approval from the Food and Drug Administration (FDA) for ALK-altered NSCLC treatment: first-generation crizotinib, second-generation (ceritinib, alectinib, and brigatinib) and third generation ALK inhibitors (lorlatinib) based on their activity in the clinic (Supplementary Table 1)111–127. The gene discussed is ALK; the disease is non-small cell lung carcinoma.